ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

ProMIS Neurosciences和其他2只股票在5美元以下，高管正在購買

Benzinga · 09/19 09:17

The Dow Jones index closed lower by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

WidePoint

The Trade: WidePoint Corporation (NYSE:WYY) CEO Jin Kang bought a total of 1,000 shares at an average price of $3.50. To acquire these shares, it cost around $3,499.
What's Happening: On Aug. 14, WidePoint posted a second-quarter GAAP loss of 5 cents per share.
What WidePoint Does: WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution.

ProMIS Neurosciences

The Trade: ProMIS Neurosciences, Inc. (NASDAQ:PMN) 10% owner Michael S Gordon acquired a total of 93,223 shares at an average price of $1.25. To acquire these shares, it cost around $116,880.
What's Happening: On Aug. 29, ProMIS Neurosciences filed for resale from time to time of 56.5 million common shares of the company by selling stockholders.
What ProMIS Neurosciences Does: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).

Emmaus Life Sciences

The Trade: Emmaus Life Sciences, Inc. (OTC:EMMA) Director Seah H. Lim acquired a total of 20,000 shares at an average price of $0.04. The insider spent around $800 to buy those shares.
What's Happening: On Sept. 10, the company said net revenues for the six months ended June 30 were $7.9 million, down from $17.5 million in the year-ago period.
What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases.

FedEx Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The Dow Jones index closed lower by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週三收盤下跌超過100點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是細價股最近幾筆值得注意的內幕交易。欲了解更多信息，請訪問Benzinga的內幕交易平台。

WidePoint

WidePo

The Trade: WidePoint Corporation (NYSE:WYY) CEO Jin Kang bought a total of 1,000 shares at an average price of $3.50. To acquire these shares, it cost around $3,499.
What's Happening: On Aug. 14, WidePoint posted a second-quarter GAAP loss of 5 cents per share.
What WidePoint Does: WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution.

交易：WidePoint Corporation（紐約證券交易所代碼：WYY）首席執行官金康共購買了1,000股股票，平均價格爲3.50美元。收購這些股票的成本約爲3,499美元。
發生了什麼：8月14日，WidePoint公佈了第二季度GAAP每股虧損5美分。
WidePoint做什麼：WidePoint Corp是技術管理即服務（TMaaS）的提供商，該服務包括聯邦認證的通信管理、身份管理、交互式賬單呈現和分析以及信息技術即服務解決方案。

ProMIS Neurosciences

ProMiS 神經科學

The Trade: ProMIS Neurosciences, Inc. (NASDAQ:PMN) 10% owner Michael S Gordon acquired a total of 93,223 shares at an average price of $1.25. To acquire these shares, it cost around $116,880.
What's Happening: On Aug. 29, ProMIS Neurosciences filed for resale from time to time of 56.5 million common shares of the company by selling stockholders.
What ProMIS Neurosciences Does: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).

交易：ProMis Neurosciences, Inc.（納斯達克股票代碼：PMN）10％的所有者邁克爾·戈登共收購了93,223股股票，平均價格爲1.25美元。收購這些股票的成本約爲116,880美元。
發生了什麼：8月29日，ProMis Neurosciences不時申請通過出售股東轉售該公司的5650萬股普通股。
ProMis Neurosciences的作用：ProMis Neurosciences Inc是一家處於臨床階段的生物技術公司，專注於研發有選擇地針對阿爾茨海默氏病（AD）、肌萎縮性側索硬化（ALS）和多系統萎縮（MSA）等神經退行性疾病中的毒性錯誤摺疊蛋白質的抗體療法。

Emmaus Life Sciences

Emmaus 生命科學

The Trade: Emmaus Life Sciences, Inc. (OTC:EMMA) Director Seah H. Lim acquired a total of 20,000 shares at an average price of $0.04. The insider spent around $800 to buy those shares.
What's Happening: On Sept. 10, the company said net revenues for the six months ended June 30 were $7.9 million, down from $17.5 million in the year-ago period.
What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases.

交易：Emmaus Life Sciences, Inc.（場外交易代碼：EMMA）董事Seah H. Lim共收購了2萬股股票，平均價格爲0.04美元。知情人士花了大約800美元購買了這些股票。
發生了什麼：9月10日，該公司表示，截至6月30日的六個月的淨收入爲790萬美元，低於去年同期的1750萬美元。
Emmaus Life Sciences的所作所爲：Emmaus Life Sciences Inc是一家生物製藥公司，主要從事罕見病和孤兒病的新療法和療法的發現、開發和商業化。

FedEx Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

聯邦快遞爲第一季度印刷做準備；以下是華爾街最準確的分析師的最新預測變化

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息